Skip to contentI
Inhibitor Therapeutics, Inc.
I
INTIInhibitor Therapeutics, Inc. Q2 2023 · 10-Q
Revenue—
Net Income-$654.52K-$654.52KN/M vs Q2 2022 EPS Diluted$0.00$0.00— vs Q2 2022 Operating Income-$742,461N/M Operating Cash Flowderived-$682,614N/M
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Inhibitor Therapeutics, Inc. · CIK 1042418 · Engraved from SEC EDGAR
ended Jun 30, 2023 · filed Aug 11, 2023 · 42 d after period end